Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance

Lim, Kenneth; Ciaccio, Pietro R Di; Polizzotto, Mark N.; Milliken, Sam; Cochrane, Tara; Goh, Zhong; Shaw, Briony; Perry, Evelyn; Gilbertson, Michael; Kermode, William; Cheah, Chan Yoon; Latimer, Maya; Hamad, Nada; Ku, Matthew

doi:10.1111/bjh.18704

Cited by 4 publications

(5 citation statements)

References 38 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to research by Lim et al, patients with HIV-DLBCL had a 2-year PFS of 77% and an OS of 81%, while those with HIV-BL had a 2-year PFS of 67% and an OS of 67% [13] , Coutinho et al showed a 5-year OS of 78% versus 64% in HIV-positive and HIV-negative DLBCL respectively [29] , in patients with HIV-DLBCL, Besson et al reported a 2-year PFS and OS of 75% and 75%, respectively [28] . Regardless of HIV status, a US retrospective research for HIV-BL reported a 3-year PFS and OS rate of 64% and 70%, respectively [30] .…”

Section: Discussionmentioning

confidence: 99%

“…Currently, the rst-line regimens used are R-CHOP-based regimens (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) and DA-EPOCH-R [11,12] . HIV-BL, which accounts for 35% of NHL subtypes, is more prevalent in PLWH with a comparatively elevated CD4 cell count [13] . The incidence of BL has not decreased throughout the ART era, in contrast to other subtypes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival of HIV associated diffuse large B-cell lymphoma, and Burkitt lymphoma in China: a 17-year retrospective study

Xiong,

Liu,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Combination antiretroviral therapy (cART) has improved outcomes for human immunodeficiency virus (HIV) associated non-Hodgkin lymphoma. This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated in China over a 17-year period during the cART and rituximab era. The median CD4 count for the cohorts was 0.141×109/L (range, 0.001–0.861×109/L). DA-EPOCH ± R (54%) were most commonly used in HIV-BL. CHOP ± R (42%) was most commonly used to treat HIV-DLBCL. The complete response rate after first-line curative therapy was 10/28 (36%) in HIV-BL and 25/57 (44%) in HIV-DLBCL. The 2-year progression-free survival (PFS) and overall survival (OS) for the HIV-BL cohort was 50% and 41% respectively. The 2-year PFS and OS for the HIV-DLBCL cohort was 55% and 47% respectively. Current China practice favours the treatment of HIV-BL and HIV-DLBCL similarly to the HIV-negative population with the use of concurrent cART. However, due to the extremely low percentage of patients receiving cART prior to the lymphoma diagnosis, the high percentage of patients with poor performance status, and the advanced stage at diagnosis, the treatment of HIV-related lymphoma remains the major challenge in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survival of HIV associated diffuse large B-cell lymphoma, and Burkitt lymphoma in China: a 17-year retrospective study

Xiong,

Liu,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Though results vary depending on the used source, some studies show how HIV patients with lymphoma diagnosis have a lower OS than patients without HIV, with no impact on PFS. Moreover, in these patients, the disease tends to have more aggressive features at diagnosis [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Primary Effusion Lymphoma, Multicentric Castleman’s Disease, and Kaposi’s Sarcoma in an HHV-8 and HIV-Positive Patient: A Case Report

et al. 2023

View full text Add to dashboard Cite

Primary effusion lymphoma (PEL), Kaposi’s sarcoma (KS), and multicentric Castleman’s disease (MCD) is an uncommon group of diseases included in the same spectrum with related characteristics. The coexistence of all of them in the same individual is a rare occurrence. We present the case of a 25-year-old patient diagnosed with human immunodeficiency virus (HIV) and the development of all these related pathologies. Despite the use of intensive treatment according to the latest recommendations, the evolution was unfavorable. This case reflects the need for new therapies and research in this field.

show abstract

“…In contrast, in a recent Spanish cohort of patients from the cART era, HIV-positive DLBCL patients had a worse prognosis with decreased overall survival at 5 years of 56% compared to 74% in HIV-negative patients [ 89 ]. A recent Australian study of HIV-positive lymphoma patients reported an excellent 2-year PFS of 77% and an OS of 81% using curative immuno-chemotherapy together with cART [ 90 ]. The frequency of HIV infection in a large cohort of DLBCL patients is 5.4% in US patients [ 23 ].…”

Section: Viral Infectionsmentioning

confidence: 99%

The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma

Gergely,

Udvardy,

Illes

2024

Biomedicines

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. The disease is very heterogeneous, with distinct genetic alterations in subtypes. The WHO 2022 5th edition classification identifies several minor groups of large B-cell lymphoma where the pathogenetic role of viruses (like EBV and HHV-8) is identified. Still, most cases fall into the group of DLBCL not otherwise specified (NOS). No review focuses only on this specific lymphoma type in the literature. The pathogenesis of this entity is still not fully understood, but several viruses and bacteria may have a role in the development of the disease. The authors review critical pathogenetic events in the development of DLBCL (NOS) and summarize the data available on several pathogenetic viruses and bacteria that have a proven or may have a potential role in the development of this lymphoma type. The possible role of B-cell receptor signaling in the microenvironment is also discussed. The causative role of the Epstein–Barr virus (EBV), human herpesvirus-8 (HHV-8), Hepatitis C virus (HCV), human immunodeficiency virus (HIV), Hepatitis B virus (HBV), and other viruses are explored. Bacterial infections, such as Helicobacter pylori, Campylobacter jejuni, Chlamydia psittaci, Borrelia burgdorferi, and other bacteria, are also reviewed.

show abstract

Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance

Cited by 4 publications

References 38 publications

Survival of HIV associated diffuse large B-cell lymphoma, and Burkitt lymphoma in China: a 17-year retrospective study

Survival of HIV associated diffuse large B-cell lymphoma, and Burkitt lymphoma in China: a 17-year retrospective study

Primary Effusion Lymphoma, Multicentric Castleman’s Disease, and Kaposi’s Sarcoma in an HHV-8 and HIV-Positive Patient: A Case Report

The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About